Physician profile
Frank Michael Bishop
NPI 1538134796
$6,954.04
in general payments reported to CMS, 2019-2025
13 companies · $4,882 in 2025
The $4,882 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,403 · 2020: $151 · 2021: $280 · 2022: $111 · 2023: $44.46 · 2024: $82.47 · 2025: $4,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,708 · Food and Beverage: $269 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,708.00 |
| Food and Beverage | $268.69 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $4,850.92 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Alcon Vision LLC | $1,121.79 | 2019-2025 | Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $340.69 | 2019-2021 | |
| Biotissue Holdings INC. | $321.89 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $67.33 | 2019 | |
| Sun Pharmaceutical Industries INC. | $60.25 | 2019-2020 | |
| Amgen INC. | $53.24 | 2024-2025 | Tepezza |
| Omeros Corporation | $33.80 | 2019 | |
| Carl Zeiss Meditec, INC. | $27.08 | 2019 | |
| Bausch & Lomb Americas INC. | $24.85 | 2023 | Vyzulta |
| Ocular Therapeutix, INC. | $23.56 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $16.66 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.